Servier Announces Outcome from the Primary Analysis of the Phase III SOLSTICE Trial Assessing LONSURF® (Trifluridine/Tipiracil) + Bevacizumab in a 1st Line Setting for Patients with Unresectable mCRC Non-eligible for Intensive Therapy

Servier announced that the primary objective of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of LONSURF® + bevacizumab over capecitabine + bevacizumab in first line unresectable metastatic colorectal cancer.